Compare Paychex, Inc. (PAYX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Paychex, Inc. trades at $114.78 (market cap $43.33B), while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). The key difference: Paychex, Inc. is far larger — about 23.3× Recursion Pharmaceuticals Inc's market cap, and Paychex, Inc. pays a 3.91% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PAYX | RXRX | |
|---|---|---|
Market Cap | $43.33B | $1.86B |
Sector | Industrials | Health |
52-Week High | $135.46 | $6.79 |
52-Week Low | $85.57 | $2.84 |
Enterprise Value | $46.81B | $1.38B |
Dividend Yield | 3.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $116.93, down 3.93% in the last session. The stock shows strong profitability with a net income margin of 27.03% and ROE of 44.77%. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.32 surpassing the $1.31 estimate. Technical indicators are mixed, with a bearish moving average signal but RSI suggesting potential oversold conditions. The company continues to expand its AI-driven WISE platform, enhancing service efficiency for small businesses.
The outlook for PAYX is cautiously optimistic, supported by robust cash flow and strategic AI integration. However, risks include elevated valuation multiples and competitive pressures in the HR solutions space. Analyst consensus is a 'Hold' with a $120 price target, indicating limited near-term upside from current levels amid balanced growth and risk factors.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
